RaySearch Laboratories AB (publ.) (STO:RAYB) has received an order for its RayStation® treatment planning system from RISO, the Radiotherapeutic Institute in Deventer, the Netherlands. RISO is a public independent radiotherapeutic institute offering radiotherapy for multiple hospitals in the region. RISO provides state-of-the-art external beam treatments and is specialized in brachytherapy for prostate cancer.
RISO will use RayStation® as its treatment planning system for conventional 3D-CRT treatments as well as more advanced treatments such as IMRT. The order includes functionality covering the full spectrum from all the necessary basic tools needed for patient segmentation and creation of conventional 3D-CRT plans, to advanced tools enabling a more efficient treatment planning process. One example is RaySearch's unique solution for multi-criteria optimization. This highly intuitive tool lets the clinician evaluate the impact of changing different treatment priorities in real time which has a large potential to speed up the time-consuming treatment planning optimization process. RISO is planning to start using the system clinically later in 2011.
"We made a thorough analysis of our options and in the end RayStation® stood out as the most innovative treatment planning system on the market today. In terms of technical features the system offers top specifications. Another important aspect for us is that RayStation's well-designed user interface also fully lives up to current software standards enabling a smooth and efficient workflow," says Rik Westendorp, medical physicist at RISO.
"This is our third European RayStation order but it is actually the first time that a clinic will use RayStation® for the whole workflow for all photon treatments from standard 3D-CRT to IMRT and VMAT. I think this is an important step in RayStation's evolution from a platform for the most advanced applications to a complete modern treatment planning system covering the everyday needs of all radiation therapy clinics," says Johan Löf, CEO of RaySearch.
Revolutionary strategy offers hope for type 1 diabetes treatment